MedTrace Logo

New Markers for Minimal Residual Disease in Acute Lymphoblastic Leukemia

NCT03249636 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 50

Last updated 2017-08-29

No results posted yet for this study

Summary

Acute lymphoblastic leukemia , also known as acute lymphocytic leukemia, characterized by the overproduction and accumulation of cancerous, immature white blood cells, known as lymphoblasts, causing damage and death by inhibiting the production of normal cells (such as red and white blood cells and platelets) in the bone marrow and by spreading (infiltrating) to other organs. Acute lymphoblastic leukemia is most common in childhood, with a peak incidence at 2-5 years of age and another peak in old age.

Conditions

Interventions

DIAGNOSTIC_TEST

Flow cytometric analysis

Level of expression of the markers and the correlation between the markers with each other and with the clinical presentation and impact on patients with ALL.

Sponsors & Collaborators

  • Assiut University

    lead OTHER

Principal Investigators

  • Maureen R Farag, Resident · Assiut University

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-12-31
Primary Completion
2019-04-30
Completion
2019-10-31

Countries

  • Egypt

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03249636 on ClinicalTrials.gov